Aspire Biopharma Holdings ( (ASBP) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aspire Biopharma Holdings has announced a delay in filing its Form 10-K (Yearly Report) for the fiscal year ending December 31, 2024. The primary reason for this delay is the need for additional time to complete its financial statements, which could not be achieved without unreasonable effort or expense. The company anticipates filing the delayed report no later than the fifth calendar day following the prescribed filing date. Aspire Biopharma Holdings has indicated that there will be no significant changes in its financial results from the previous fiscal year. The company remains committed to compliance, with CEO Kraig T. Higginson signing the notification.
More about Aspire Biopharma Holdings
YTD Price Performance: -94.40%
Average Trading Volume: 547,759
Technical Sentiment Signal: Buy
For detailed information about ASBP stock, go to TipRanks’ Stock Analysis page.